The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes

Podobne zapisy

• Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52‐week, randomized, multicenter trial
  od: Seino, Yutaka, i wsp.
  Wydane: (2011)
• Fifty‐two‐week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon‐like peptide‐1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
  od: Kaku, Kohei, i wsp.
  Wydane: (2011)
• Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
  od: Kiyosue, Arihiro, i wsp.
  Wydane: (2017)
• The Glucagon-Like Peptide 1 Analog Liraglutide Impairs the Migration of Rat Intestinal Cells in vitro
  od: Aline Gabriely Torres Duarte, i wsp.
  Wydane: (2025-11-01)
• Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study
  od: Miyagawa, J., i wsp.
  Wydane: (2015)